Lund University Publications
https://lup.lub.lu.se/search
Lund University Lund University Publications2000-01-01T00:00+00:001dailyEconomic Burden of Parkinson’s Disease : A Multinational, Real-World, Cost-of-Illness Study
https://lup.lub.lu.se/search/publication/74353d89-6c1a-474d-ae5e-41e8efbd4646
Chaudhuri, K. RayAzulay, Jean PhilippeOdin, PerLindvall, SusannaDomingos, JosefaAlobaidi, AliKandukuri, Prasanna L.Chaudhari, Vivek S.Parra, Juan CarlosYamazaki, ToruOddsdottir, JuliaWright, JackMartinez-Martin, Pablo2024Background: Parkinson’s disease is now one of the fastest-growing neurodegenerative disorders in the developed world, with an increasing prevalence and associated socioeconomic costs. Progression of the disease leads to a gradual deterioration in patients’ quality of life, despite optimal treatment, and both medical and societal needs increase, often with the assistance of paid and/or unpaid caregivers. Objective: We aimed to quantify the incremental economic burden of Parkinson’s disease by disease severity in a real-world setting across differing geographic regions. Methods: Demographics, clinical characteristics, health status, patient quality of life, caregiver burden, and healthcare resource utilization data were drawn from the Adelphi Parkinson’s Disease Specific Program™, conducted in the USA, five European countries, and Japan. Results: A total of 563 neurologists provided data for 5299 individuals with Parkinson’s disease; 61% were male, with a mean age of 64 years. Approximately 15% of individuals were deemed to have advanced disease, with significantly more comorbidities, and a poorer quality of life, than those with non-advanced disease. Overall, the mean annual healthcare resource utilization increased significantly with advancing disease, and resulted in a three-fold difference in the USA and Europe. The main drivers behind the high economic burden included hospitalizations, prescription medications, and indirect costs. Conclusions: People with Parkinson’s disease, and their caregivers, incur a higher economic burden as their disease progresses. Future interventions that can control symptoms or slow disease progression could reduce the burden on people with Parkinson’s disease and their caregivers, whilst also substantially impacting societal costs.https://lup.lub.lu.se/record/74353d89-6c1a-474d-ae5e-41e8efbd4646http://dx.doi.org/10.1007/s40801-023-00410-1scopus:85181904450pmid:38193999engDrugs - Real World Outcomes; (2024)ISSN: 2199-1154NeurologyEconomic Burden of Parkinson’s Disease : A Multinational, Real-World, Cost-of-Illness Studycontributiontojournal/articleinfo:eu-repo/semantics/articletextHomocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease : clinical and therapeutic considerations
https://lup.lub.lu.se/search/publication/fc16d740-c74c-436f-9cd4-a0d7668130b1
Phokaewvarangkul, OnanongBhidayasiri, RoongrojGarcia-Ruiz, PedroOdin, PerRiederer, PeterMüller, Thomas2023Emerging studies suggest a correlation between elevated plasma homocysteine (hcy) levels and the risk of atherosclerosis, vascular disorders, and neurodegenerative diseases, including Parkinson's disease (PD). This narrative review delves into the intricate relationships between Hcy, vitamin B metabolites, dopamine-substituting compounds, and various symptoms of PD. Patients undergoing a long-term L-dopa/dopa-decarboxylase inhibitor (DDI) regimen, especially without a concurrent catechol-O-methyl transferase (COMT) inhibitor or methyl group-donating vitamin supplementation, such as vitamins B6 and B12, exhibit an elevation in Hcy and a decline in vitamin B metabolites. These altered concentrations appear to be associated with heightened risks of developing non-motor symptoms, including peripheral neuropathy and cognitive disturbances. The review underscores the impact of levodopa metabolism via COMT on homocysteine levels. In light of these findings, we advocate for the supplementation of methyl group-donating vitamins, notably B6 and B12, in patients undergoing a high-dose L-dopa/DDI regimen, particularly those treated with L-dopa/carbidopa intestinal gel (LCIG) infusion.https://lup.lub.lu.se/record/fc16d740-c74c-436f-9cd4-a0d7668130b1http://dx.doi.org/10.1007/s00702-023-02684-9pmid:37603058scopus:85168449679engJournal of Neural Transmission; 130(11), pp 1451-1462 (2023)ISSN: 0300-9564NeurologyHomocysteineLevodopaNeuropathyParkinson’s diseaseVitamin B metabolitesHomocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease : clinical and therapeutic considerationscontributiontojournal/systematicreviewinfo:eu-repo/semantics/articletext